CSF synuclein: Adding to the biomarker footprint of dementia with Lewy bodies

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 6, 2010, Pages 590-591

  Mollenhauer, Brit ^a,b   Schlossmacher, Michael G ^c  

^a Paracelsus Elena Klinik   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; PROTEOME; TRANSCRIPTOME;

ALZHEIMER DISEASE; AMYLOIDOSIS; AUTOPSY; CEREBROSPINAL FLUID; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE COURSE; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; LEWY BODY; METABOLOME; NERVE DEGENERATION; PARKINSON DISEASE; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; TAUOPATHY;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; HUMANS; LEWY BODY DISEASE;

EID: 77953714113     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2010.206391     Document Type: Editorial

References (4)

1. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863-72.
2. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 2000;920:16-27. (Pubitemid 32056547)
3. Kasuga K, Tokutake T, Ishikawa A, et al. Differential levels of alpha-synuclein, beta-Amyloid42, and Tau in cerebrospinal fluid between patients with demementia with lewy bodies and Alzheimer disease. J Neurol Neurosurg Psychiatry 2010;81:608-10.
4. Mollenhauer B, Cullen V, Kahn I, et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008;213:315-25.